Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients

Translational Research

Volumn 151, Issue 4, 2008, Pages 217-223

  Chang, Horng Rong ^a,b   Kuo, Wu Hsien ^c   Hsieh, Yih Shou ^b   Yang, Shun Fa ^b   Lin, Chiu Chu ^b   Lee, Mei Lan ^b   Lian, Jong Da ^a,b   Chu, Shu Chen ^c  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYSTATIN C; GELATIN; GELATINASE A;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; REGRESSION ANALYSIS; UNIVARIATE ANALYSIS; ZYMOGRAPHY;

EID: 40849133852     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2007.12.004     Document Type: Article

References (41)

1. Zhang R., Kumar P., Ramcharan T., and Reisin E. Kidney transplantation: the evolving challenges. Am J Med Sci 328 (2004) 156-161
2. Chapman J.R., O'Connell P.J., and Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 16 (2005) 3015-3026
3. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., and Chapman J.R. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 78 (2004) 461-468
4. Lenz O., Elliot S.J., and Stetler-Stevenson W.G. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11 (2000) 574-581
5. Woessner Jr. J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5 (1991) 2145-2154
6. Lelongt B., Legallicier B., Piedagnel R., and Ronco P.M. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases?. Curr Opin Nephrol Hypertens 10 (2001) 7-12
7. Tanney D.C., Feng L., Pollock A.S., and Lovett D.H. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis. Dev Dyn (1998) 213 121v9
8. Ota K., Stetler-Stevenson W.G., Yang Q., et al. Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor. Kidney Int 54 (1998) 131-142
9. Davies M., Martin J., Thomas G.J., and Lovett D.H. Proteinases and glomerular matrix turnover. Kidney Int 41 (1992) 671-678
10. Lods N., Ferrari P., Frey F.J., et al. Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 14 (2003) 2861-2872
11. Rao V.H., Lees G.E., Kashtan C.E., et al. Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS). Kidney Int 63 (2003) 1736-1748
12. Duymelinck C., Deng J.T., Dauwe S.E., De Broe M.E., and Verpooten G.A. Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int 54 (1998) 804-818
13. Norman J.T., and Lewis M.P. Matrix metalloproteinases (MMPs) in renal fibrosis. Kidney Int 54 (1996) S61-S63
14. Cheng S., Pollock A.S., Mahimkar R., Olson J.L., and Lovett D.H. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 20 (2006) 1898-1900
15. Del Prete D., Anglani F., Forino M., et al. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40 (1997) 1449-1454
16. Inkinen K.A., Soots A.P., Krogerus L.A., Lautenschlager I.T., and Ahonen J.P. Fibrosis and matrix metalloproteinases in rat renal allografts. Transpl Int 18 (2005) 506-2
17. Lutz J., Yao Y., Song E., et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 79 (2005) 655-661
18. Rodrigo E., Lopez-Hoyos M., Escallada R., et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy. Nephrol Dial Transplant 15 (2000) 2041-2045
19. Palomar R., Mayorga M., Ruiz J.C., et al. Markers of fibrosis in early biopsies of renal transplants. Transplant Proc 37 (2005) 1468-1470
20. Filler G., Bokenkamp A., Hofmann W., Le Bricon T., Martinez-Bru C., and Grubb A. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem 38 (2005) 1-8
21. Kuo W.H., Chou F.P., Lu S.C., Chu S.C., and Hsieh Y.S. Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers. Clin Chim Acta 294 (2000) 157-168
22. Chen T.Y., Hsieh Y.S., Yang C.C., et al. Relationship between matrix metalloproteinase-2 activity and cystatin C levels in patients with hepatic disease. Clin Biochem 38 (2005) 632-638
23. Liu S.C., Yang S.F., Yeh K.T., et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 371 (2006) 92-96
24. Qin L.X., and Tang Z.Y. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 8 (2002) 385-392
25. Corbel M., Belleguic C., Boichot E., and Lagente V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 18 (2002) 51-61
26. Lee S.W., Song K.E., Shin D.S., et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 69 (2005) 175-179
27. Kleiner D.E., and Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218 (1994) 325-329
28. Yang S.F., Hsieh Y.S., Lin C.L., et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in non-small cell lung cancer patients. Clin Chim Acta 354 (2005) 91-99
29. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Hsiao T.Y., and Lu K.H. The clinical significance of gelatinase B in gouty arthritis of the knee. Clin Chim Acta 339 (2004) 77-83
30. Lovett D.H., Sterzel R.B., Kashgarian M., and Ryan J.L. Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney Int 23 (1983) 342-349
31. McMillan J.I., Riordan J.W., Couser W.G., Pollock A.S., and Lovett D.H. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 97 (1996) 1094-1101
32. Davies M., Thomas G.J., Martin J., and Lovett D.H. The purification and characterization of a glomerular-basement-membrane-degrading neutral proteinase from rat mesangial cells. Biochem J 251 (1988) 419-425
33. Akiyama K., Shikata K., Sugimoto H., et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 95 (1997) 115-128
34. Steinmann-Niggli K., Ziswiler R., Kung M., and Marti H.P. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 9 (1998) 397-407
35. Chang H.R., Yang S.F., Li M.L., Lin C.C., Hsieh Y.S., and Lian J.D. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 366 (2006) 243-248
36. Chou F.P., Chu S.C., Cheng M.C., et al. Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 35 (2002) 383-388
37. Catania J.M., Chen G., and Parrish A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292 (2007) F905-F911
38. Preston G.A., Barrett C.V., Alcorta D.A., et al. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron 92 (2002) 817-823
39. Joosten S.A., Sijpkens Y.W., van Kooten C., and Paul L.C. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 68 (2005) 1-13
40. Chu S.C., Wang C.P., Chang Y.H., et al. Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin Chim Acta 341 (2004) 133-138
41. Asanuma K., Shirato I., Ishidoh K., Kominami E., and Tomino Y. Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int 62 (2002) 822-831